Cemiplimab as a hope for a young patient with aggressive squamous cell carcinoma of the sacrococcygeal region

Abstract

Cemiplimab is a new and effective immunotherapy molecule from the group of checkpoint inhibitors (anti-PD1) for the treatment of patients with metastatic or locally advanced squamous cell carcinoma of the skin who are not suitable for curative surgery or curative radiation.

Keywords

• skin cancer
• cemiplimab
• radiotherapy
• immunotherapy
• wound